More data stressing innovative "nontraditional" approaches to the antibiotic management of community-acquired pneumonia, such as home intravenous treatment and therapy with oral antibiotics, are ...

Adjunct Corticosteroids in Children Hospitalized With Community-Acquired Pneumonia Weiss AK, Hall M, Lee GE, Kronman MP, Sheffler-Collins S, Shah SS Pediatrics . 2011;127:e255-263 ...

Community-acquired pneumonia (CAP) is an important cause of hospital admission and death, but the extent of the problem of CAP at the primary healthcare level is largely unknown. To investigate ...

(HealthDay News) — Community-acquired pneumonia (CAP) is associated with increased risk of long-term adverse events, according to a study published online June 11 in the American Journal of ...

--Nabriva Therapeutics plc, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that The ...

In a new study, most patients with community-acquired pneumonia did not receive testing for influenza, even during influenza season, researchers reported in Chest.“Other than CDC surveillance ...

The FDA has approved the supplemental New Drug Application (sNDA) for Baxdela (delafloxacin; Melinta Therapeutics) for the treatment of community acquired bacterial pneumonia (CABP) in adult patients.

Met all Primary and Secondary Efficacy Endpoints and Was Generally Safe and Well-ToleratedLargest Clinical Data Set in Pneumonia for Any Antibiotic Approved in the Last DecadeLabel Update ...

HONOLULU — The risk for all-cause mortality was reduced among patients with community-acquired pneumonia who used hydrocortisone vs. other corticosteroids, according to a poster presented at the ...

BOSTON, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today that new data from its omadacycline clinical and microbiology programs will be presented at ...

-Post Hoc analysis published in The Journal of Emergency Medicine demonstrates patients with moderate to severe CABP can be managed effectively as outpatients with a 5-day, monotherapy regimen of ...